PDGFR Inhibitor Crenolanib in Children/Young Adults With Diffuse Intrinsic Pontine Glioma or Recurrent High-Grade Glioma
Status:
Completed
Trial end date:
2016-10-01
Target enrollment:
Participant gender:
Summary
This is a Phase I clinical trial evaluating crenolanib (CP-868,596), an inhibitor of Platelet
Derived Growth Factor Receptor (PDGFR)-kinase in children and young adults with newly
diagnosed diffuse intrinsic pontine glioma (DIPG) (Stratum A) or in recurrent, progressive or
refractory High Grade Glioma (HGG) including DIPG (Stratum B). This study drug targets the
most commonly amplified region of genome found in DIPG and pediatric high grade glioma (HGG)
which encodes for the PDGF receptor kinase. An oral investigational agent crenolanib will be
administered daily during and after local radiation therapy (RT) in Diffuse Intrinsic Pontine
Glioma DIPG (Stratum A), or daily for children with recurrent/refractory HGG (Stratum B).
Phase:
Phase 1
Details
Lead Sponsor:
St. Jude Children's Research Hospital
Collaborators:
Arog Pharmaceuticals, Inc. The V Foundation for Cancer Research